{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:33:53Z","timestamp":1793136833156,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mayocp.2025.09.017","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:34:10Z","timestamp":1764578050000},"page":"2228-2236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-126X","authenticated-orcid":false,"given":"Bibek","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayvardhan","family":"Kamalumpundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don C.","family":"Codipilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2025.09.017_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065425","article-title":"Trends in body mass index, overweight and obesity among adults in the USA, the NHANES from 2003 to 2018: a repeat cross-sectional survey","volume":"12","author":"Li","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.mayocp.2025.09.017_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","article-title":"Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice","volume":"119","author":"Camilleri","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.09.017_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"18","key":"10.1016\/j.mayocp.2025.09.017_bib4","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.3390\/jcm13185627","article-title":"Impact of GLP-1 receptor agonists in gastrointestinal endoscopy: an updated review","volume":"13","author":"Singh","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.09.017_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.mayocp.2025.09.017_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.mayocp.2025.09.017_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.mayocp.2025.09.017_bib8","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist\u2013induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.mayocp.2025.09.017_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.mayocp.2025.09.017_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.mayocp.2025.09.017_bib11","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"1 suppl 1","key":"10.1016\/j.mayocp.2025.09.017_bib12","first-page":"S266","article-title":"13. Older adults: standards of care in diabetes\u20132025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mayocp.2025.09.017_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1502050","article-title":"Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs","volume":"15","author":"Gao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.mayocp.2025.09.017_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mayocp.2025.09.017_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.mayocp.2025.09.017_bib16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1\u2013based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2025.09.017_bib17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2025.09.017_bib18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.mayocp.2025.09.017_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.09.017_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.gie.2024.10.011","article-title":"Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis","volume":"101","author":"Singh","year":"2025","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"10.1016\/j.mayocp.2025.09.017_bib21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002564","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy","volume":"119","author":"Yao","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mayocp.2025.09.017_bib22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.14309\/ajg.0000000000003362","article-title":"Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy: a systematic review and meta-analysis","volume":"120","author":"Beran","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.09.017_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.gie.2024.07.014","article-title":"Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study","volume":"101","author":"Odah","year":"2025","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"10.1016\/j.mayocp.2025.09.017_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA Rapid Clinical Practice Update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mayocp.2025.09.017_bib25","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","author":"Kindel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625005518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625005518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:43:47Z","timestamp":1764578627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625005518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025619625005518"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.09.017","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}